Suppr超能文献

用于 PSMA 的正电子发射断层扫描成像的 Ti 靶向示踪剂。

Ti targeted tracers for PET imaging of PSMA.

机构信息

Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

出版信息

Nucl Med Biol. 2022 May-Jun;108-109:16-23. doi: 10.1016/j.nucmedbio.2022.01.005. Epub 2022 Feb 4.

Abstract

PURPOSE

Positron Emission Tomography is an important molecular imaging technique for detection and diagnoses of various disease states. This work aims to develop novel titanium-45 (t = 3.08 h) PET tracers using Prostate Specific Membrane Antigen (PSMA) targeting vectors for imaging of prostate cancer as proof of concept for this relatively unexplored isotope.

PROCEDURES

Titanium-45 was produced on the University of Alabama at Birmingham (UAB) TR24 cyclotron using proton bombardments on natural scandium foils and separated using procedures described previously [1]. After purification, Titanium-45 was used to radiolabel two PSMA-targeting molecules; DFO-DUPA and LDFC-DUPA. Radiochemical yields were determined via radio-high purity liquid chromatography (radioHPLC). The radiolabeled compounds were tested both in vitro and in vivo using PSMA+ cell lines (LNCaP and 22Rv1) and PSMA- cell lines (PC3).

RESULTS

Titanium-45 was produced and purified in yields suitable for research studies. Radiochemical yields of up to 98 ± 1% were achieved with DFO-DUPA and 92 ± 7% with LDFC-DUPA. PSMA specific targeting was observed in vitro in PSMA positive cells (LNCaP (0.6% ± 0.05%) and confirmed by blocking (0.15% ± 0.04%) (P < 0.0001)), compared to uptake in the PSMA negative cells (PC3 (0.07% ± 0.008%)) and confirmed by blocking (0.07% ± 0.01%) (P = 0.5253). In vivo studies demonstrated statistically significant uptake in LNCaP tumors (2.3% ± 0.3% ID/g) compared to PC3 tumor uptake (0.1% ± 0.07%).

CONCLUSIONS

This work shows that titanium-45 can be used to radiolabel PSMA targeting compounds with high radiochemical yields. These radiolabeled compounds remain intact in serum for at least two half-lives of titanium-45, showing that these compounds would be appropriate for implementation in the clinical setting. This study shows the feasibility of using titanium-45 as positron emitting radiometal for use in imaging PSMA+ prostate cancer, and illustrates that further research is in this area is warranted.

摘要

目的

正电子发射断层扫描是一种重要的分子影像学技术,可用于检测和诊断各种疾病状态。本研究旨在开发新型钛-45(t = 3.08 h)正电子发射断层扫描放射性示踪剂,使用前列腺特异性膜抗原(PSMA)靶向载体对前列腺癌进行成像,以此作为该相对未开发同位素的概念验证。

程序

钛-45 是在阿拉巴马大学伯明翰分校(UAB)TR24 回旋加速器上通过质子轰击天然钪箔产生的,并使用以前描述的程序进行分离[1]。纯化后,使用钛-45 标记两种 PSMA 靶向分子;DFO-DUPA 和 LDFC-DUPA。通过放射性高效液相色谱法(radioHPLC)确定放射性化学产率。使用 PSMA+细胞系(LNCaP 和 22Rv1)和 PSMA-细胞系(PC3)在体外和体内测试了标记化合物。

结果

成功生产和纯化了适合研究的钛-45。DFO-DUPA 的放射性化学产率高达 98 ± 1%,LDFC-DUPA 的放射性化学产率高达 92 ± 7%。在 PSMA 阳性细胞(LNCaP(0.6% ± 0.05%))中观察到 PSMA 特异性靶向,并用阻断剂(0.15% ± 0.04%)(P < 0.0001)证实,与 PSMA 阴性细胞(PC3(0.07% ± 0.008%))的摄取相比,用阻断剂(0.07% ± 0.01%)(P = 0.5253)证实。体内研究表明,LNCaP 肿瘤的摄取量有统计学意义(2.3% ± 0.3% ID/g),而 PC3 肿瘤的摄取量(0.1% ± 0.07%)。

结论

本研究表明,钛-45 可用于高放射性化学产率标记 PSMA 靶向化合物。这些标记化合物在钛-45 的至少两个半衰期内仍保持完整,表明这些化合物适用于临床应用。本研究表明,使用钛-45 作为正电子发射放射性金属来成像 PSMA+前列腺癌是可行的,并说明该领域需要进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验